Skip to main content
Springer logoLink to Springer
. 2016 Aug 6;30(5):537. doi: 10.1007/s10557-016-6684-z

Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Robert S Rosenson 1,✉, Terry A Jacobson 2, David Preiss 3, Stephen C Djedjos 4, Ricardo Dent 5, Ian Bridges 6, Michael Miller 7
PMCID: PMC6828239  PMID: 27497929

Erratum to: Cardiovasc Drugs Ther (2016) 30:305-313

DOI 10.1007/s10557-016-6666-1

The original version of this article unfortunately contained a mistake. In the Results of the Abstract section, where it says "…compared to −6 % vs. placebo and −39 % vs. ezetimibe…" it should read "…compared to −65 % vs. placebo and −39 % vs. ezetimibe …".

Footnotes

The online version of the original article can be found at 10.1007/s10557-016-6666-1.


Articles from Cardiovascular Drugs and Therapy are provided here courtesy of Springer

RESOURCES